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ABSTRACT
Invasive fungal diseases are associated with a
high morbidity and mortality, particularly in
the context of immunosuppression. Diagnosis
of invasive fungal diseases is usually compli-
cated by factors such as poor clinical suspicion
and unspecific clinical findings. Access to
modern diagnostic tools is frequently limited in
developing countries. Here, we describe five
real-life clinical cases from a Brazilian tertiary
hospital, in order to illustrate how to best select
diagnostic tests in patients with different fungal
infections.
Keywords: Antigen detection; Beta-D-glucan;
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INTRODUCTION
Invasive fungal diseases (IFD) are important
causes of mortality and morbidity in immuno-
compromised patients, including individuals
suffering from hematological diseases, trans-
plant recipients, and those under critical care or
chemotherapy. Diagnosis of IFDs is complicated
by several factors: tests based on antibody
detection have low sensitivity, culture-based
methods may require a long time to yield pos-
itive results, and biopsies for histopathologic
examination can be hazardous for many of the
severely ill patients. Finally, experience is nee-
ded from pathologists in order to perform a
proper diagnosis, and biomarkers might be
expensive and/or not widely available. There-
fore, there is an urgent need to facilitate access
to modern diagnostic tests, and also to wisely
use current available diagnostic methods, aim-
ing for an early initiation with appropriate
antifungal therapy.
Here, we describe five real-life clinical situa-
tions of IFD in which diagnostic methods were
required. All patients were selected in a refer-
ence transplant centre located in Porto Alegre,
southern Brazil. The purpose of this review is to
perform a practical approach by selecting cases
from real life as examples of challenges related
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to the diagnosis of IFDs. In accordance, it
should be noted that clinical decisions were
made by the attending physicians, and these
did not necessarily align with current interna-
tional guidelines. Informed consent was
obtained from all patients for being included in
the study.
CASE 1
A 35-year-old female patient from Rondonia (a
Brazil northern state) had been submitted to
kidney transplantation 5 years ago. She was
using tacrolimus and prednisone (2.5 mg daily).
She presented with a 2-month history of fever,
night sweats and fatigue with no respiratory
symptoms. A chest magnetic resonance imaging
showed multiple bilateral pulmonary nodules,
up to 2.5 cm in diameter (Fig. 1). She was put on
empirical treatment for tuberculosis. Serum
cryptococcal antigen (latex agglutination test)
and Histoplasma immune diffusion test were
negative. Bronchoscopy was performed and
microscopic examination of bronchoalveolar
lavage (BAL) fluid was negative for fungi. BAL
galactomannan (GM) index was 0.3. An open
lung biopsy was performed and revealed a
granulocytic infiltrate, with spherical budding
structures suggestive of Histoplasma capsulatum
(small ovate yeast-like forms at
Grocott-Gomori’s methenamine silver stain-
ing). Culture of BAL fluid (Sabouraud dextrose
agar) was also positive for H. capsulatum (iden-
tification of the mycelial form of H. capsulatum
at 25 C and yeast conversion at 37 C).
Despite the endemic presence of H. capsula-
tum in Latin America, histoplasmosis is unusual
in other parts of the world, except for the Mis-
sissippi river valley (US). Histoplasmosis seems
to be a rare condition after solid organ trans-
plant (SOT) in most parts of the globe. For
instance, the Transplant-Associated Infection
Surveillance Network (TRANSNET) studied 23
transplant centers in the United States and
described the 1-year cumulative incidence of
histoplasmosis as 0.1%. Although not frequent
in this cohort, histoplasmosis was the most
endemic fungal infection seen in the study,
with 34% of cases occurring [2 years post
transplantation [1]. Moreover, its incidence
appears to be increasing: a survey of histoplas-
mosis-associated hospitalizations in the US
revealed an annual percent change in trans-
plant patients of ?12.9% over 2002–2012 [2]. It
is clear that, in this case, the medical team did
not initially think about disseminated histo-
plasmosis. However, there is plenty of data
revealing a high frequency of histoplasmosis in
Brazil—in which the southern states and the
Amazon are the most affected regions. The
patient reported here came from an Amazon
state and and the transplant was performed in
the south.
Difficulties in achieving an accurate myco-
logical diagnosis in SOT recipients include
unspecific clinical syndromes. In transplant
recipients, skin lesions (frequent in AIDS
patients with disseminated disease) are unusual
[3–5]. The absence of respiratory symptoms, as
described in this case, made the diagnosis even
more challenging. Histoplasmosis seems to fol-
low a more aggressive and rapid course in
transplant patients, and clinical awareness is
critical for an early diagnosis and intervention.
The differential diagnosis in this patient
includes tuberculosis, histoplasmosis, paracoc-
cidioidomycosis, and invasive pulmonary
aspergillosis. There is no reliable non-invasive
and non-culture-based diagnostic test in this
scenario capable of excluding the diseases
Fig. 1 Magnetic resonance imaging of the thorax, demon-
strating bilateral pulmonary nodules (Case 1)
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considered in differential diagnosis. Besides the
risk associated with the performance of invasive
medical procedures (such as the pulmonary
biopsy performed in the case), it is to be noted
that an experienced pathologist is ultimately
needed to correctly identify Histoplasma from
histopathologic specimens. This is a small
yeast-like fungal pathogen that can easily be
overlooked in the hands of an inexperienced
physician.
In the microbiology laboratory, Histoplasma
may take several weeks to grow, and specific
culture media such as Sabouraud dextrose agar
or Agar Mycosel are required. Therefore, waiting
for culture results may not be the best strategy,
since prompt initiation of effective antifungal
therapy is essential for this disseminated disease
[6].
Histoplasma antigen detection allows for an
early diagnosis of disseminated histoplasmosis.
These are non-invasive and relatively rapid tests
that do not require culture for diagnosis. In SOT
recipients, antigen detection is the most
important method for the early diagnosis of
progressive disseminated histoplasmosis [7, 8].
Antibody detection, as ordered in this case, is of
limited use due to its low sensitivity. In a large
case series of histoplasmosis in SOT recipients,
antigenuria detection was the most sensitive
diagnostic method, presented in 93% of the
cases. As expected, antigen was more frequently
detected in this study in patients with dissemi-
nated histoplasmosis, in comparison to pul-
monary disease only (97% vs. 73%, respectively)
[7]. Unfortunately, in countries with the high-
est burden of disease, access to these diagnostic
tests remains very limited. Most tests are based
on enzyme immunoassay (ELISA), but poin-
t-of-care lateral flow technologies should be
available in the near future.
Regarding Histoplasma nucleic acid detec-
tion, there is as yet no available commercial kit
and few laboratories perform polymerase chain
reaction (PCR) tests for the diagnosis of histo-
plasmosis. Therefore, even though PCR may be
a more cost-effective and versatile diagnostic
tool in this setting, this review will focus on
Histoplasma antigen detection, which is cur-
rently the most important test to detect dis-
seminated histoplasmosis.
As shown in this case, it is quite common for
patients with histoplasmosis to first receive
(inappropriately) therapy against M. tuberculo-
sis. This may not only delay diagnosis but also
result in toxicities and drug–drug interactions.
In summary, histoplasmosis represents a
tough diagnostic challenge, mainly due to the
unavailability of modern diagnostic tools like
Histoplasma antigen detection, in combination
with limited clinical suspicion.
CASE 2
A 37-year-old man presented with a 2-week story
of dry cough and progressive dyspnoea. He had
been submitted to an allogeneic hematopoietic
cell transplant procedure for a refractory acute
myeloid leukemia 4 months before hospital
admission. The patient developed grade III
graft-versus-host disease (GVHD). He was taking
cyclosporine and prednisone 10 mg daily. He
received prophylaxis with posaconazole oral
solution (200 mg daily) in the first 15 days fol-
lowing transplantation (during the neutropenia
phase, as per local protocol). A chest computed
tomography revealed a bilateral interstitial infil-
trate andmultiple nodules with amaximum size
of 1.3 cm, without halos (Fig. 2). He was
non-neutropenic at this time. Bronchoscopywas
performed and BAL fluid analysis was negative
for fungi (microscopy and culture). The BAL GM
index was 0.9. An open lung biopsy revealed
Fig. 2 Computerized tomography of the thorax, showing
multiple pulmonary nodules and patchy inﬁltrates (Case 2)
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invasion by branched hyphae, suggestive of
Aspergillus sp. Voriconazole was initiated at
standarddoses but the patient died 6 days later of
respiratory failure and dysfunction of multiple
organs and systems. Cultures of the lung speci-
men were negative.
This was a transplant recipient who had
undergone posaconazole prophylaxis and who
developed an IFD 3 months after the end of the
30-day prophylactic regimen. Posaconazole pro-
phylaxis represents a safe and effective strategy
against fungal infections in transplant patients
[9, 10]. Although there is an ongoing debate
regarding the optimal approach to the preven-
tion of IFD in allogeneic stem cell transplant
recipients, recent guidelines support the use of
prophylactic antifungal agents in these patients,
particularly in the context of GVHD [11, 12].
There are important differences between
aspergillosis in neutropenic hosts and in
non-neutropenic hosts [13]. In neutropenic
hosts, angioinvasion is a hallmark of the disease
and this is associated with a high frequency of
dissemination to other organs. In this scenario,
classic radiologic findings such as pulmonary
nodules and the halo sign are commonly seen.
Serum GM, a cell wall component of many
fungi including Aspergillus species, can be
detected in the sera using a commercial test
(Platelia Aspergillus EIA; BioRad). GM testing is
particularly useful for neutropenic patients
when serum samples are tested—its high nega-
tive predictive value ([98%) in this context
contributes greatly in the management of these
individuals [13–15].
Invasive aspergillosis in the non-neutropenic
host is typically not associated with angioinva-
sion. Symptoms of disease are often unspecific
and the clinical course is most often subacute.
Typical radiologic hallmarks may also be absent,
with a plethora of other pulmonary abnormal-
ities. GM detection in the serum of non-neu-
tropenic hosts is also of limited interest due to
its limited sensitivity [16]. However, GM detec-
tion in BAL samples is of great utility in
non-neutropenic hosts [17, 18]. The absence of
appropriate suspicion of invasive aspergillosis in
non-neutropenic patients frequently leads to a
delayed diagnosis and a poor outcome, with
many cases only diagnosed post-mortem [13].
The case reported here did not represent a
breakthrough IFD, since the patient was
exposed to posaconazole [100 days before
developing IFD. However, there are some
interesting aspects related to the diagnosis of
IFD in patients undergoing antifungal prophy-
laxis that deserve discussion. We should all bear
in mind that GM testing in serum samples has
been validated in neutropenic individuals
not receiving antifungal prophylaxis against
Aspergillus species. In patients receiving
anti-Aspergillus antifungal prophylaxis, GM
should better be avoided as a tool for preemp-
tive antifungal therapy (due to its reduced test
sensitivity in this context) but rather as a diag-
nostic-driven strategy for patients with a sus-
pected IFD [19].
As for the other azoles, posaconazole has
pharmacokinetic properties that require thera-
peutic drug monitoring (TDM) to assure that
serum drug levels are adequate. In prophylactic
regimens, however, there is no consensus on
the need for serum drug measurements, since
posaconazole achieves high tissue concentra-
tions that do not necessarily correlate with
serum levels [20]. But considering the formula-
tion and the dose used by our patient, TDM
could have been recommended as good clinical
practice. Unfortunately, azole drug monitoring
is not available in most medical centers in Latin
America, even though posaconazole is being
widely incorporated in the antifungal arma-
mentarium in transplant centers.
GM testing using a lateral flow device is a
new and promising (rapid) diagnostic method
with a performance comparable to that of both
PCR and classical GM testing (ELISA). Recent
data, however, indicate that, in the presence of
mold-active antifungal prophylaxis or treat-
ment, sensitivity of this method drops to 52%,
thereby compromising its utility in this scenario
[21].
Molecular methods like Aspergillus PCR pro-
mise to improve diagnosis, but a lack of stan-
dardization precludes their wide use [22].
Recently, many efforts have been made in order
to standardize Aspergillus PCR [22–24]. There is
as yet no consensus on how these tests could be
used in the diagnostic strategy, and many issues
arise, such as difficulties in the differentiation
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between infection and colonization [23]. A
quantitative measurement of Aspergillus DNA
could help on this regard, but this remains to be
proved [25]. Aspergillus PCR is expected to be
included in the next EORTC/MSG definitions of
invasive fungal disease [22, 23].
Although this review article is devoted to the
diagnosis of IFD and not therapy, the authors
recognize that treating an IFD with voricona-
zole in a patient previously exposed to
posaconazole is not recommended. Since lung
tissue obtained by biopsy from this patient was
not cultured, we should refer to this as a case of
hyalohyphomycosis (which includes fusariosis
and scedosporiosis) and not necessarily invasive
aspergillosis. Even though a positive GM test in
this context strongly suggests the diagnosis of
IA, it is well known that infections caused by
Fusarium species may also result in positive GM
tests [26]. Treatment with a polyene would be




of headache and fever. He had been submitted to
kidney transplantation 8 months before hospital
admission and was taking tacrolimus (4 mg
daily) and prednisone (10 mg daily). Physical
examination revealed an erythematous lesion on
the right forearm (10 cm in diameter), associated
with local edema. Chest computed tomography
imaging was normal. Serum cryptococcal anti-
gen detection was positive (titer, 1:64; latex
agglutination test). Amphotericin B deoxy-
cholate was initiated (1 mg/kg/day). 5-Fluorocy-
tosine (5-FC)wasnot available. Lumbar puncture
revealed a cerebrospinal fluid (CSF) with 12 leu-
cocytes/mm3; microscopy was negative for fungi
and cryptococcal antigen detection was positive
(titer, 1:32). After 5 days of antifungal therapy,
his clinical condition improved, with regression
of skin lesions. Fungal culture in the CSF was
negative and the skin lesion was not biopsied.
The most important risk factor for crypto-
coccosis is HIV infection. Today, HIV infection
accounts for up to 80% of cryptococcal disease
globally. However, other populations, such as
corticosteroid and/or immunosuppressive ther-
apies including solid organ transplantation
recipients, are also at risk [28, 29]. In a signifi-
cant parcel of patients, no identifiable risk fac-
tor is determined [29]. Cryptococcosis is
currently one of the most important oppor-
tunistic infections affecting renal transplant
recipients [30].
Most cryptococcal infections (95%) are
caused by Cryptococcus neoformans (serotype A),
but the other 4–5% are caused by C.neoformans
(serotype D) and C. gattii (serotype B–C). C.
gattii has an endemic behavior and is associated
to eucalyptus trees in tropical and subtropical
climates.
The most common site of extra-pulmonary
infection is the central nervous system. In this
case, the patient presented with skin lesions.
Atypical disease presentations may result in
poor outcomes because of delays in diagnosis
and treatment; nevertheless, skin lesions are a
well-described manifestation in renal transplant
patients [28, 30–32]. Skin lesions in cryptococ-
cosis are pleomorphic and a biopsy is crucial for
diagnosis, facilitating diagnosis of this poten-
tially lethal condition. Patients using tacrolimus
are more likely to develop skin lesions. Tacroli-
mus is a calcineurin inhibitor and has in vitro
activity against Cryptococcus. Cyclosporine A
also has anti-cryptococcal activity, but a lower
penetration in the CNS. Therefore, these effects
could in part explain the higher frequency of
extra-neural presentations seen in patients
using tacrolimus, particularly when compared
to HIV patients [33].
Cryptococcus can be cultured frommost sites.
In AIDS-related cryptococcal meningitis, the
sensitivity of CSF and blood cultures are *90%
and *50–70%, respectively [34]. Cultures can
distinguishbetween the two species, using a solid
agar medium containing canavanine, glycine
and bromothymol blue (CGB agar). When C.
gattii is growing, a positive color change from
yellow–green to cobalt blue is noted with CGB
[35, 36]. Even though is a relatively cheap test,
CGB isnotwidely available inmostmicrobiology
laboratories around the world.
Cryptococcal antigen detection (CrAg) is a
valuable tool for early diagnosis of cryptococ-
cosis. The two main techniques available are
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latex agglutination (LA) and enzyme
immunoassay (EIA), performed either in the
cerebrospinal fluid or serum [28]. LA sensitivi-
ties and specificities vary from 93% to 100% and
from 93% to 98%, respectively, regarding the
detection of C. neoformans [28]. However, LA
has reduced sensitivity for C. gattii detection,
whilst EIA shows reduced sensitivity for ser-
otype C and D [34]. LA requires laboratory
equipment and refrigeration of reagents, and is
an ultimately manual test with subjectivity in
the interpretation of the result [34]. Most of
these characteristics also apply to EIA, with the
additional disadvantages of higher cost and
turnaround time. Due to these limitations, their
use in resource-limited settings is problematic.
Nevertheless, these tests have been considered
standards of care for over 35 years [28, 34, 37].
Recently, an immune chromatographic lat-
eral flow assay (CrAg LFA; Immuno-Mycologics,
Norman, OK, USA) has been designed in order
to overcome the need for a rapid and accurate
diagnosis, in settings with limited access to
laboratory infrastructure. LFA has a sensitivity
and specificity[98%, and a shorter turnaround
time in comparison to LA/EIA (only 15 min)
[28, 34, 37]. LFA can also detect C. gattii, an
additional advantage in comparison to the
other CrAg test on the market. LFA is also
cheaper than its comparators. However, expe-
rience with LFA remains limited in transplant
patients, including kidney transplant recipients
[37].
Therefore, screening for cryptococcal disease
may be warranted in transplant patients, with a
special attention to kidney transplant recipi-
ents. Immunosuppressed patients with skin
lesions with any type should always be consid-
ered for fungal disease, including cryptococco-
sis. Antigen testing has a central role in
diagnosis, and point-of-care methodologies like
LFA need to be appropriately evaluated in this
context.
CASE 4
A 56-year-old diabetic woman with chronic kid-
ney disease under peritoneal dialysis presented
with a 2-week history of fever and abdominal
pain. Peritoneal fluid analysis revealed 240 leu-
cocytes/mm3 (60% were lymphomonocytes).
Glucose concentration was normal in the peri-
toneal fluid, and adenosine deaminase was
reduced. No bacteria were detected. She was
empirically treated with piperacillin/tazobactam
for 8 days,without improvement. The peritoneal
catheter was removed and a new peritoneal fluid
sample obtained. The catheter was not sent for
culture. Fluid analysis demonstrated 200 leuco-
cytes/mm3 and no bacterial growth. Instead,
fungal hyphae were detected and identified as
Trichoderma sp., by matrix-assisted laser desorp-
tion/ionization time-of-flightmass spectrometry
(MALDI-TOFMS). Amphotericin B deoxycholate
(0.9 mg/kg/day) was initiated and the patient
improved clinically. Despite the fungal infection
treatment, she died 10 days later as a result of a
methicillin-resistant Staphylococcus aureus sepsis.
Here, we describe a rare fungal infection
causing peritonitis in a patient on continuous
ambulatory peritoneal dialysis (CAPD). Most
CAPD-related infections are due to bacteria,
mainly Gram-positive rods. Only a small fraction
(*3–10%) are caused by fungi, and the most
common fungal etiology is Candida sp. Fungal
peritonitis inCAPDpatientshas ahighmorbidity
and mortality. Fungi have always to be consid-
ered as a potential causative agent of CAPD-as-
sociated peritonitis when bacterial cultures of
peritoneal fluid are negative [38].Trichoderma sp.
is a saprotrophic fungus commonly found in the
soil. Trichoderma sp. have been associated with
skin infections, and also peritonitis, brain
abscess, sinusitis and disseminated infections.
Mortality may be as high as 50% [38].
Considering the detection of hyphae in the
peritoneal fluid, correct identification is critical
for the adequate therapy. Here, we illustrate the
important need for mycology laboratories for
proper fungal identification. Trichoderma
hyphae appear smooth-walled, hyaline septate
and branched, characteristics similar to other
agents of hyalohyphomycoses like Aspergillus
and Fusarium [38, 39]. Trichoderma can be
identified by the colony aspect on Sabouraud
dextrose agar and by morphological features of
the conidia and phialides. However, cultures
may take several days to demonstrate growth
and require experienced personnel for
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procedures and correct identification [39]. In
this context, MALDI-TOF MS has emerged as a
revolutionary tool for rapid identification, dif-
ferentiation and classification of microorgan-
isms. Filamentous fungi such as Aspergillus,
Fusarium and even Trichoderma can be identified
using MALDI-TOF. This technology can provide
an accurate and rapid diagnose at the species
level, which is particularly important in the
scenario described, in which classic methods are
prone to misidentification and delays [40–42].
Studies have confirmed the discriminatory
power and accuracy of MALDI-TOF MS for
fungi, overcoming morphological analysis (by
time and reliability) and molecular identifica-
tion (by cost, feasibility and availability)
[41, 42]. Unfortunately, MALDI-TOF MS is still
not widely available in developing countries
like Brazil.
In this case, removal of the dialysis catheter
and prompt initiation of antifungal therapy
were crucial to patient management. Tricho-
derma susceptibility to antifungals is variable
(which reinforces the need for antifungal sus-
ceptibility testing, which was performed in this
case). Most isolates of Trichoderma sp. show
resistance to fluconazole and 5-FC. Ampho-
tericin B and azoles have variable resistance.
Voriconazole have been used, with success, to
treat disseminated infections. The role of com-
bination antifungal therapy remains unclear
[39].
CASE 5
A 24-year-old woman with Crohn’s disease
taking mesalazine (3 g daily) and corticosteroids
was hospitalized for a long period due to a
perforated intestine and bacterial peritonitis.
She was currently taking meropenem and van-
comycin and started a new fever and hypoten-
sion. Blood cultures were collected and
anidulafungin was initiated. Candida orthopsilo-
sis was recovered in blood cultures. After
12 days of treatment, the blood cultures were
still positive (six positive cultures in a 12-day
interval), and a transoesophageal echocardiog-
raphy showed a 5-cm-sized thrombus at the
extremity of a central venous catheter, with no
vegetation on the cardiac valves. Despite
25 days of antifungal therapy, she remained
febrile, with persistent fungemia. Divergences
between the medical and surgical teams led to a
marked delay in catheter removal. After the
catheter was surgically removed, the patient
became afebrile within 3 days, with negative
blood cultures.
Candidemia is related to many known risk
factors, and abdominal surgical procedures
(especially those involving hollow viscera) are
one of the most important. Our patient was also
in the hospital for a long period, and used
broad-spectrum antibiotics. This scenario rep-
resents a high chance of invasive Candida
infection [43].
Invasive Candida infections, particularly
candidemia, are on the rise in the hospital sce-
nario [44, 45]. In an US point-prevalence mul-
ticenter study, Candida spp. was the most
frequent etiology for primary bloodstream
infections [44]. In developing countries such as
Brazil, incidence is still increasing, and mortal-
ity remains high ([40%), despite the availability
of modern antifungal drugs such as the
echinocandins in the antifungal armamentar-
ium [46].
Recently, non-C. albicans species have been
identified as a frequent cause of hospital infec-
tion. C. parapsilosis is the second most common
species isolated from the blood in Latin Ameri-
can countries and the third most common in
the US. [47]. Molecular studies demonstrated
heterogeneity into this species, and divided it
into three groups based in its genetic charac-
teristics. The former C. parapsilosis group II was
re-designated as C. orthopsilosis [48, 49].
Blood cultures are the gold standard for the
diagnosis of candidemia. Nevertheless, this tra-
ditional methodology lacks sensitivity (around
50–70%) and 3–4 days may be required for
positive results, characteristics that preclude its
reliability in the critically ill patient. Delays in
starting antifungal therapy are correlated to a
worse prognosis: patients receiving appropriate
antifungal therapy on the first day after cultures
have an estimated mortality of 24%, increasing
to 37% and 41%, respectively, if therapy is
started 1 and 2 days later [50, 51].
Infect Dis Ther
Beta-D-glucan (BDG), a fungal cell wall
component, is a biomarker that has been largely
studied for the diagnosis of invasive Candida
infections. It was included in the last EORTC/
MSG definitions of invasive fungal infections
[52, 53]. Even though significant heterogeneity
exists among studies evaluating the perfor-
mance of BDG, a meta-analysis found a pooled
sensitivity of 76.8% [95% confidence interval
(CI), 67.1–84.3%] and 85.3% specificity (95% CI
79.6–89.7%) [53]. Therefore, BDG testing offers
a much better sensitivity in comparison to the
current gold-standard, blood culture. However,
BDG is a high-cost and labour-intensive test,
and is currently unavailable in most developing
countries. Due to its high negative predictive
value, BDG testing has the potential to allow for
antifungal therapy to be withheld [54], but the
economic impact of such intervention has yet
to be determined.
T2 Magnetic Resonance Assay (T2MR) is a
promising, novel methodology that uses man-
ual application of magnetic resonance to detect
Candida species in whole blood samples, with a
turnaround time of less than 3 h. This test has a
sensitivity of 91% and specificity of 98%. The
extremely accurate and rapid diagnosis that
does not require culture may radically chance
the management of invasive Candida infections,
with a potential impact on patient mortality
[55].
Since C. orthopsilosis is also (as C. parapsilosis)
a potent biofilm producer, catheter removal is
essential in order to obtain the best clinical
outcomes. In the case described here, the
catheter was not removed in the first place. This
may have led to the formation of biofilm
around the device and the persistence of the
infection. Catheter removal is a necessity in
invasive Candida infections [43] and must
always be performed when feasible.
CONCLUSION
Management of IFDs requires an accurate diag-
nosis, but unfortunately modern diagnostic
tools in the mycology laboratory are scarce in
most parts of the world. In this review article,
we provide readers with illustrative clinical
cases obtained from a developing country, in an
attempt to discuss what diagnostic tests should
be available, and the advantages and difficulties
in incorporating such novel technologies.
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